Skip to main content
Premium Trial:

Request an Annual Quote

Bayer, Leica Biosystems Collaborate on CDx for Cancer Therapies

NEW YORK (GenomeWeb) – Bayer and Leica Biosystems said today they will collaborate on the development of a companion diagnostic that employs immunohistochemistry and RNAscope, a multiplex nucleic acid hybridization technology, to test cancer tissue.

Financial terms of the agreement were not disclosed.

Under the terms of the deal, Leica will provide expertise in assay development, regulatory approval, and commercialization of companion diagnostic tests for targeted anticancer therapies developed by Bayer.

Leica Vice President of Pharma Partnerships Jonathan Roy said that the agreement with Bayer will help to expand the firm's menu of companion diagnostic tests based on its BOND technology — an automated IHC/ISH staining platform — and that the collaboration supports its mission of advancing cancer diagnostics.

Leica has a collaboration to automate Advanced Cell Diagnostics' RNAscope on the BOND platform.

“This represents another important step for Bayer towards a more personalized approach in the fight against cancer,” Bayer AG's Head of Drug Discovery Andreas Busch said in a statement.

Bayer has established partnerships with several external partners that specialize in the development of companion diagnostic tests based on blood or tissue samples.

The firm said that early screening for patient-specific tumor markers will help in the design of more efficient clinical trials and "eventually increase the probability of therapeutic success for patients suffering from cancer."

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more